Samuel G Schumacher

List of Publications by Year
in descending order

72 papers	3,704 citations	186209 28 h-index	143943 57 g-index
76 all docs	76 docs citations	76 times ranked	3611 citing authors

#	Article	IF	Citations
1	Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infectious Diseases, The, 2022, 22, 242-249.	4.6	47
2	Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. The Cochrane Library, 2022, 2022, CD014841.	1.5	14
3	Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape. EBioMedicine, 2022, 82, 104174.	2.7	11
4	Accuracy of a Novel Urine Test, Fujifilm SILVAMP Tuberculosis Lipoarabinomannan, for the Diagnosis of Pulmonary Tuberculosis in Children. Clinical Infectious Diseases, 2021, 72, e280-e288.	2.9	34
5	â€œI got tested at home, the help came to meâ€: acceptability and feasibility of homeâ€based TB testing of household contacts using portable molecular diagnostics in South Africa. Tropical Medicine and International Health, 2021, 26, 343-354.	1.0	11
6	Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study. Lancet Infectious Diseases, The, 2021, 21, 376-384.	4.6	25
7	Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2021, 2021, CD012768.	1.5	63
8	Diagnostic Accuracy Study of a Novel Blood-Based Assay for Identification of Tuberculosis in People Living with HIV. Journal of Clinical Microbiology, 2021, 59, .	1.8	36
9	Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. The Cochrane Library, 2021, 2021, CD009593.	1.5	58
10	Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid. Journal of Clinical Microbiology, 2021, 59, .	1.8	13
11	Accuracy of the Truenat MTB-RIF Dx assay for detection of rifampicin resistance-associated mutations. Tuberculosis, 2021, 127, 102064.	0.8	7
12	Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study. European Respiratory Journal, 2021, 58, 2003999.	3.1	12
13	A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays. European Respiratory Journal, 2021, 58, 2100526.	3.1	33
14	Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. The Cochrane Library, 2021, 2021, CD012972.	1.5	16
15	A novel blood-based assay for treatment monitoring of tuberculosis. BMC Research Notes, 2021, 14, 247.	0.6	9
16	Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. The Cochrane Library, 2021, 2021, .	1.5	3
17	Evaluation of the diagnostic performance of laboratory-based c-reactive protein as a triage test for active pulmonary tuberculosis. PLoS ONE, 2021, 16, e0254002.	1.1	13
18	Analytical performance of the Xpert MTB/XDRÂ® assay for tuberculosis and expanded resistance detection. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115397.	0.8	12

#	Article	IF	Citations
19	Retrospective Diagnostic Accuracy Study of Abbott RealTi m e MTB against Xpert MTB/RIF Ultra and Xpert MTB/RIF for the Diagnosis of Pulmonary Tuberculosis and Susceptibility to Rifampin and Isoniazid Treatment. Microbiology Spectrum, 2021, 9, e0013221.	1.2	0
20	Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. European Respiratory Journal, 2021, 57, 2000747.	3.1	16
21	Equivalence of the GeneXpert System and GeneXpert Omni System for tuberculosis and rifampicin resistance detection. PLoS ONE, 2021, 16, e0261442.	1.1	2
22	â€œSILVAMP TB LAMâ€•Rapid Urine Tuberculosis Test Predicts Mortality in Patients Hospitalized With Human Immunodeficiency Virus in South Africa. Clinical Infectious Diseases, 2020, 71, 1973-1976.	2.9	12
23	A pre-clinical validation plan to evaluate analytical sensitivities of molecular diagnostics such as BD MAX MDR-TB, Xpert MTB/Rif Ultra and FluoroType MTB. PLoS ONE, 2020, 15, e0227215.	1.1	10
24	Advances in Molecular Diagnosis of Tuberculosis. Journal of Clinical Microbiology, 2020, 58, .	1.8	83
25	Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data. PLoS Medicine, 2020, 17, e1003113.	3.9	54
26	Effect of history of tuberculosis on specificity of Xpert MTB/RIF. European Respiratory Journal, 2020, 56, 2000343.	3.1	3
27	Diagnostic Accuracy of a Novel and Rapid Lipoarabinomannan Test for Diagnosing Tuberculosis Among People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2020, 7, ofz530.	0.4	36
28	Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV. European Respiratory Journal, 2020, 55, 1901259.	3.1	36
29	Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. Lancet Respiratory Medicine,the, 2020, 8, 368-382.	5.2	58
30	Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. Journal of Clinical Investigation, 2020, 130, 5756-5764.	3.9	53
31	The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis. PLoS Medicine, 2020, 17, e1003466.	3.9	10
32	Title is missing!. , 2020, 17, e1003113.		0
33	Title is missing!. , 2020, 17, e1003113.		0
34	Title is missing!. , 2020, 17, e1003113.		0
35	What if They Donâ€™t Have Tuberculosis? The Consequences and Trade-offs Involved in False-positive Diagnoses of Tuberculosis. Clinical Infectious Diseases, 2019, 68, 150-156.	2.9	24
36	Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. Journal of Infectious Diseases, 2019, 220, S99-S107.	1.9	19

#	Article	IF	Citations
37	Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles. Journal of Infectious Diseases, 2019, 220, S91-S98.	1.9	17
38	Guidance for Studies Evaluating the Accuracy of Rapid Tuberculosis Drug-Susceptibility Tests. Journal of Infectious Diseases, 2019, 220, S126-S135.	1.9	10
39	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. Journal of Infectious Diseases, 2019, 220, S116-S125.	1.9	33
40	The impact of Xpert MTB/RIFâ€"do we have a final answer?. The Lancet Global Health, 2019, 7, e161-e162.	2.9	7
41	Screening for tuberculosis: time to move beyond symptoms. Lancet Respiratory Medicine,the, 2019, 7, 202-204.	5.2	22
42	Guidance for Studies Evaluating the Accuracy of Biomarker-Based Nonsputum Tests to Diagnose Tuberculosis. Journal of Infectious Diseases, 2019, 220, S108-S115.	1.9	38
43	Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Library, 2019, 6, CD009593.	1.5	144
44	Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Research, 2019, 4, 173.	0.9	2
45	Improving the design of studies evaluating the impact of diagnostic tests for tuberculosis on health outcomes: a qualitative study of perspectives of diverse stakeholders. Wellcome Open Research, 2019, 4, 183.	0.9	3
46	Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. Wellcome Open Research, 2019, 4, 173.	0.9	2
47	Impact of diagnostic test Xpert MTB/RIFÂ® on health outcomes for tuberculosis. The Cochrane Library, 2018, , .	1.5	6
48	Diagnostic Test for Incipient Tuberculosis: A Step Forward, Many More to Go. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1106-1107.	2.5	6
49	Surrogate endpoints in global health research: still searching for killer apps and silver bullets?. BMJ Global Health, 2018, 3, e000755.	2.0	44
50	Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infectious Diseases, The, 2018, 18, 76-84.	4.6	474
51	Xpert^{Â®}MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. The Cochrane Library, 2018, 8, CD012768.	1.5	153
52	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	5.7	353
53	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	3.1	27
54	Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2017, 49, 1601075.	3.1	100

#	Article	IF	Citations
55	XpertÂ® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. The Cochrane Library, 2017, , .	1.5	4
56	The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. MBio, 2017, 8, .	1.8	431
57	Comparative accuracy of the REBA MTB MDR and Hain MTBDRplus line probe assays for the detection of multidrug-resistant tuberculosis: A multicenter, non-inferiority study. PLoS ONE, 2017, 12, e0173804.	1.1	6
58	Estimated clinical impact of the Xpert MTB/RIF Ultra cartridge for diagnosis of pulmonary tuberculosis: A modeling study. PLoS Medicine, 2017, 14, e1002472.	3.9	50
59	Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection. Annals of Internal Medicine, 2016, 165, 345.	2.0	135
60	Diagnostic Test Accuracy in Childhood Pulmonary Tuberculosis: A Bayesian Latent Class Analysis. American Journal of Epidemiology, 2016, 184, 690-700.	1.6	52
61	Multicenter Noninferiority Evaluation of Hain GenoType MTBDR plus Version 2 and Nipro NTM+MDRTB Line Probe Assays for Detection of Rifampin and Isoniazid Resistance. Journal of Clinical Microbiology, 2016, 54, 1624-1630.	1.8	61
62	Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis. PLoS ONE, 2016, 11, e0150054.	1.1	19
63	Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies. PLoS ONE, 2016, 11, e0151073.	1.1	37
64	Impact of point-of-care implementation of Xpert^{Â®} MTB/RIF: product vs. process innovation. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1084-1090.	0.6	13
65	Xpert^{Â®} MTB/RIF for extra-pulmonary tuberculosis: time to look beyond accuracy. International Journal of Tuberculosis and Lung Disease, 2015, 19, 2-2.	0.6	4
66	The Seasonality of Tuberculosis, Sunlight, Vitamin D, and Household Crowding. Journal of Infectious Diseases, 2014, 210, 774-783.	1.9	77
67	Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 2014, 44, 435-446.	3.1	413
68	Performance of Xpert MTB/RIF on pleural tissue for the diagnosis of pleural tuberculosis: Table 1â€“. European Respiratory Journal, 2013, 42, 1427-1429.	3.1	53
69	Challenges in the Development of an Immunochromatographic Interferon-Gamma Test for Diagnosis of Pleural Tuberculosis. PLoS ONE, 2013, 8, e85447.	1.1	4
70	Immunodiagnosis of Tuberculosis: State of the Art. Medical Principles and Practice, 2012, 21, 4-13.	1.1	42
71	Evaluation of bleach-sedimentation for sterilising and concentrating Mycobacterium tuberculosis in sputum specimens. BMC Infectious Diseases, 2011, 11, 269.	1.3	13
72	Optimizing Tuberculosis Testing for Basic Laboratories. American Journal of Tropical Medicine and Hygiene, 2010, 83, 896-901.	0.6	10